Mac Concordia
@macconcordia.bsky.social
Reposted by Mac Concordia
Merck is changing the way Keytruda is delivered, from an IV infusion to a subcutaneous injection, so it can thwart biosimilar competition and continue price gouging people with cancer.
It's a tactic known as “product hopping" and it's a form of patent abuse. Here’s how it works.
It's a tactic known as “product hopping" and it's a form of patent abuse. Here’s how it works.
May 20, 2025 at 2:42 PM
Merck is changing the way Keytruda is delivered, from an IV infusion to a subcutaneous injection, so it can thwart biosimilar competition and continue price gouging people with cancer.
It's a tactic known as “product hopping" and it's a form of patent abuse. Here’s how it works.
It's a tactic known as “product hopping" and it's a form of patent abuse. Here’s how it works.